The Food and Drug Administration provided information on the website and reported the blood pressure medications that they contain carcinogens. Here's what to look out for.
Macleods Pharmaceuticals Limited remembers 32 many of the popular blood pressure enhancer losartan after discovering traces of a probable carcinogen.
The recalled tablets of losartan and potassium / hydrochlorothiazide combination contained small amounts of N-nitrosodiethylamine or NDEA according to a company listing posted on the Food and Drug Administration website on Wednesday.
"Based on available information, the risk of developing cancer in a few patients due to prolonged use of the product cannot be excluded," the recall report says.
The active drug component was produced by Hetero Labs Limited in India, one of the foreign drug factories associated with repeated blood drugs recalls since July last year.
Macleods also recalled part of the losartan combination drug in February for the same reason. The company stated in the statement that for this recall no reports of adverse reactions have been received.
MacBook Pro recall: Apple voluntary recall of batteries on MacBook Pro notes due to security risk
Fisher-Price remembers 4.7 million infant swords after reported death  CLOSE